Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

wyeth Bear, Stearns & Co. Healthcare Conference

899 views

Published on

  • Be the first to comment

  • Be the first to like this

wyeth Bear, Stearns & Co. Healthcare Conference

  1. 1. Bear Stearns Healthcare Conference Jim Connolly Executive Vice President and General Manager Wyeth Vaccines September 10, 2007
  2. 2. Forward-Looking Statement The statements in this presentation that are not historical facts are forward- looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, the impact of competitive or generic products, product liability and other types of lawsuits, the impact of legislative and regulatory compliance and obtaining approvals, and patent, and other risks and uncertainties, including those detailed from time to time in Wyeth’s periodic reports, including quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Quarterly results, in particular, can vary due to issues which include, but are not limited to, changes in exchange rates, the timing of actions taken by the Company to ensure long- term improvements to our manufacturing processes, the timing of regulatory approval of new products and/or facilities and the timing of promotional programs. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. 2 jcBearStearns09102007_5
  3. 3. Key Messages Wyeth is a leader in vaccines and very excited about n future prospects Wyeth developed first “blockbuster” vaccine – Prevnar n - Success has changed view on potential for vaccines Major growth opportunities remain in pneumococcal n disease area – infants and adults Strong, innovative pipeline comprised of significant n first- or best-in-class opportunities 3
  4. 4. Poised for Significant Growth Strong Significant Business Growth Characteristics Opportunities •Long product •Unmet medical needs life cycles •New technologies •High barriers to entry •Emerging markets •100+ year history of innovation •Prevnar – 1st blockbuster vaccine •Exciting R&D pipeline Wyeth Position 4 jcBearStearns09102007_5
  5. 5. Prevnar – Outstanding Efficacy Profile …and adults …in children (from herd immunity) Average Incidence of Vaccine Serotype (>50 Years of Age) 90 35 Prelicensure Prelicensure 80 IPD per 100,000 Population Estimated Cases/100,000 30 (1998-1999) (1998-1999) 70 Postlicensure Postlicensure 25 (2003) (2002-2003) 60 20 50 55% 40 15 Reduction 30 10 20 94% Reduction 5 10 0 0 Average for 1998 2003 Average for 1998 2003 and 1999 and 1999 WHO SAGE Recommendation: WHO SAGE Recommendation: “Recognizing the burden of pneumococcal disease occurring in young children and “Recognizing the burden of pneumococcal disease occurring in young children and the safety and efficacy of PCV-7 in this age group, WHO considers that it should be the safety and efficacy of PCV-7 in this age group, WHO considers that it should be aapriority to include this vaccine in the national immunization programmes…” priority to include this vaccine in the national immunization programmes…” MMWR. 2005;Vol: 54(No. 36):893-897. 5 jcBearStearns09102007_5
  6. 6. Prevnar – Strong Global Growth First Half 2007 Growth Current Status Registered Countries 89 United States $578 +13% Launched Countries 84 EMEA 508 +50% Current National Latin America 94 +118% 16 Programs Asia Pacific 69 +24% National Programs 6 Announced* TOTAL $1,249 +31% * Includes Ireland, Denmark, Cyprus, New Zealand, Costa Rica and Peru 6
  7. 7. Prevnar – Growth Potential x Double Sales by 2010 2009 • New Launches $4 • NIPs • Compliance/Catch-up $3 B + • Emerging Markets $3 Sales ($ Billions) $2 $1.5 B $1 $0 2005A 2009E Source: Wyeth internal sales data, 2007 7
  8. 8. Prevnar – Redefining The Possible Total Market Potential $6.0 B Emerging Markets Total Emerging/Developing Potential $3.5 B Total Developed Market Potential $2.5 B Prevnar 2006 $2.0 B Prevnar Penetration: Penetration: Prevnar 33% 73% Penetration: 4% 8
  9. 9. Promising Pipeline Market Opportunity Phase 3 13v Infant Phase 3 13v Adult $35 $30 B + PCV Infant PCV Adult Mng B Phase 2 $30 Mng B S aureus ACC-001 Phase 2 (Alzheimers $25 GAS HIV Therapeutic) Sales ($B) HCV Alzheimer's $20 Phase 1 HIV / AIDS $15 Group A Strep Pre-clin. $10 Staph Aureus Pre-clin. $5 Hepatitis C Pre-clin. $2 B Therapeutic $0 2006 Sales Future Market Opportunity 9
  10. 10. Prevnar 13 – Expanding the Coverage • Provide broadest coverage available for the global protection of children Opportunity against pneumococcal disease • Phase 2 proof of concept achieved • Licensing criteria agreed upon Status • Worldwide phase 3 studies ongoing • Submission early 2009 > $3 Billion Peak Sales 10
  11. 11. Prevnar – 7v vs. 13v Achieved Proof of Concept – Phase 2 Infant Study % Subjects Achieving Correlate of Protection 100 % subjects > 0.35 ug/ml 75 50 25 0 4 6B 9V 14 18C 19F 23F 1 3 5 6A 7F 19A PCV7 PCV13 11
  12. 12. Emerging Pneumococcal Serotype Profile Pre & Post Prevnar Serotypes Superior Coverage in the U.S. in US Children <2 7v vs 10v vs 13v Serotype Coverage 1998-1999 Serotypes 2003 Comparison – U.S. PCV7 23F 7v 10v 13v 19F 18C 14 Pre-Prevnar® (1998) 81% 9V 6B Post-Prevnar (2003) 17% 4 22% 60% 7F 5 Prevnar has greatly reduced serious disease caused 1 by the 7 vaccine-associated serotypes 19A A 10v vaccine provides only marginal additional 6A coverage 3 13v PnC will provide substantial coverage in 70 60 50 40 10 0 20 30 40 50 30 20 0 10 the U.S. and superior coverage in other Cases of IPD countries Source: CDC data 12
  13. 13. Prevnar 13 – Expanding to Adults Provide first and only conjugate n vaccine that offers adults, age 50 and above, an opportunity to Opportunity prevent pneumococcal pneumonia for the rest of their lives Proof of concept achieved n Licensing criteria agreed upon n Status Worldwide phase 3 studies n ongoing Submission late 2009 n Peak Sales > $1.5 Billion 13
  14. 14. Adult Pneumococcal Vaccine Opportunity Cases of Invasive Pneumococcal Disease (IPD) U.S. Population (2010) 65+ -- 40.2 Million Cases per 100,000 50 50-64 -- 58.4 Million 40 30 20 IPD 10 0 <1 1 2 to 4 5 to 17 18 to 34 35 to 49 50 to 64 65+ Non-bacteremic Deaths per 100,000 10 Pneumonia 9 8 7 6 5 4 3 2 1 0 <1 1 2 to 4 5 to 17 18 to 34 35 to 49 50 to 64 65+ Source: CDC data 14
  15. 15. Redefine Adult Opportunity Prevnar 13 23 v Polysaccharide Prevnar 13 23 v Polysaccharide Potential Profile Current Profile Potential Profile Current Profile Antibody titers and efficacy Superior antibody decline after 5 years1 responses Induces hyporesponsiveness2 No hyporesponsiveness and boostable No demonstrated efficacy Opportunity to demonstrate vs. pneumonia in elderly effectiveness in pneumonia Generally recommended Extend age range of for adults 65+ protection to 50+ 1 Shapiro, et al, NEJM 1991 2 Torling, et al, Vaccine 2003 15
  16. 16. Meningococcal Group B Vaccine % Incidence By Group Medical Need Devastating disease that n causes meningitis and sepsis High mortality ~ 10-15% n Serious sequelae in 20-30% n of survivors Occurs endemically and in n outbreaks US EU No global vaccine available for n Group B Meningitis Market potential: > $4 B B C Y W A Other n *Source: Prevention and Control of Meningococcal Disease, Recommendations of the Advisory Committee on Immunization Practices (ACIP), May 27, 2005 / 54(RR07);1-21, MMWR. EU-IBIS meningococcal data - 2004 16
  17. 17. Group B Meningococcal (MngB) Program In-house discovery of MngB surface protein n (LP 2086) covering > 90% of Group B isolates Vaccine candidate appears safe and immunogenic n in Phase 1 trials (Adults) Phase 1 / 2 in adolescents and toddlers / infants n ongoing Initiated discussions on regulatory pathway n 17
  18. 18. Summary and Conclusions Wyeth is a leader in vaccines and very excited about n future prospects Wyeth developed first “blockbuster” vaccine – Prevnar n - Success has changed view on potential for vaccines Major growth opportunities remain in pneumococcal n disease area – infants and adults Strong, innovative pipeline comprised of significant n first- or best-in-class opportunities 18

×